CAR T cells for severe lupus
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell treatment (BCMA-CD19 cCAR T cells) for people with lupus that has not responded well to standard therapies. It may help reduce lupus disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 70 years old.
- You have had lupus for at least 6 months, diagnosed by standard criteria.
- You have tried at least 2 standard lupus treatments that did not work well enough.
- You have active lupus symptoms (score of 7 or higher on a lupus activity scale).
- You do not have a history of CAR-T therapy, organ transplant, or serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new CAR T-cell therapy (C-CAR168) for people with lupus nephritis that has not responded to standard treatments. It aims to see if this therapy can help control the disease.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.